CombiGene was granted €3.3 million from the SME Instrument, HORIZON 2020, phase 2.
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders.
The aim of the project is development and commercialization of the company’s gene therapy project focusing on difficult-to-treat epilepsy.
GAEU helped structuring the project and build a strong business case. The project is complex and at an early stage, and the innovation arguments are because of this very essential to a successful application. We made a big difference by preparing the client for the pitch deck in Brussels by providing coaching, and designing the presentation. We also helped the team to prepare for the interview in Brussels.
GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience of the complex application procedure and the professional hands-on support that we got throughout the entire process were very valuable. I look forward to a continued cooperation with them in the future.
Jan Nilsson, CEO, CombiGene